Neuropharmacological evidence for an interaction between the GABA uptake inhibitor Cl‐966 and anxiolytic benzodiazepines
- 1 January 1990
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 21 (3) , 217-225
- https://doi.org/10.1002/ddr.430210307
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Initial human safety and tolerance study of a GABA uptake inhibitor, Cl‐966: Potential role of GABA as a mediator in the pathogenesis of schizophrenia and maniaDrug Development Research, 1990
- Type I and Type II GABA A -Benzodiazepine Receptors Produced in Transfected CellsScience, 1989
- Importance of a novel GABAA receptor subunit for benzodiazepine pharmacologyNature, 1989
- Structural and functional basis for GABAA receptor heterogeneityNature, 1988
- Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-familyNature, 1987
- High affinity [3H]zolpidem binding in the rat brain: an imidazopyridine with agonist properties at central benzodiazepine receptorsEuropean Journal of Pharmacology, 1986
- Potentiation by intraventricular muscimol of the anticonflict effect of benzodiazepinesBrain Research, 1980
- Molecular Mechanisms in the Receptor Action of BenzodiazepinesAnnual Review of Pharmacology and Toxicology, 1979
- Dependence, Tolerance, and Addiction to Benzodiazepines: Clinical and Pharmacokinetic ConsiderationsDrug Metabolism Reviews, 1978
- Uptake and metabolism of γ-aminobutyric acid by neurones and glial cellsBiochemical Pharmacology, 1975